genOway and Cyagen have joined forces to form a long-term strategic partnership in the Asia-Pacific region

2020

Partnership

News
-
December 1, 2020

Lyon, France, December 1, 2020 – genOway and Cyagen, two innovative companies and leaders in the creation of genetically engineered rodent models, announced a partnership to commercialize high-standard preclinical humanized immune checkpoint and immunodeficient BRGSF mouse models to nonprofit and for-profit organizations in the Asia-Pacific region from 2020 on.

“We are very excited by this strategic partnership with Cyagen,” said Alexandre Fraichard, founder and General Manager of genOway. “Excellency in science and customer focus are the core values of both companies. This partnership will enable genOway and Cyagen to serve their customers better, by offering them the most advanced and comprehensive portfolio of preclinical mouse models with the necessary intellectual property rights, and help accelerate their research in immuno-oncology and immune-therapy.”

“Cyagen and genOway are among the leaders in the field of genetically engineered models. This alliance will allow our customers in the Asia-Pacific region to access the more scientifically advanced immunodeficient and humanized immune checkpoint mouse models,” Mr. Lanqing Han (Lance), Chairman of Cyagen, said. “Importantly, these models have been co-validated by a consortium of leading immuno-oncology companies (e.g., AbbVie, AstraZeneca, BMS, Pfizer, and Roche), and some of them have been already published in prestigious scientific journals and provided data for IND.”

This agreement enables Cyagen to produce, sell and distribute preclinical humanized immune checkpoint and immunodeficient BRGSF mouse models developed by genOway in most of the APAC countries.

About Cyagen

Cyagen is an 800-employee company headquartered in Santa Clara, California, with additional locations in Japan and China. As one of the leading providers of genetically engineered mouse and rat models, Cyagen is renowned for its quality, money-back guarantee, and cost-effective prices. Cyagen provides researchers around the world with transgenic, knockout, knock-in, CRISPR, and ES-cell based models and also offers a comprehensive series of stem cell products for research use, including cell lines, media and differentiation kits. From vector and strategy design to animal model creation, cryopreservation and breeding, Cyagen offers complete outsourcing for all animal model needs. Cyagen has served thousands of top laboratories and pharmaceutical companies worldwide over the past 15 years. Its products and services have been cited in over 4,300 publications in high-impact academic journals.

About genOway

Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway is an international team that employs passionate and dedicated people from 18 nationalities. Its clients include 380 academic institutions and 170 life sciences companies, with 17 of the top 20 pharma. genOway strives to become the preferred partner of all scientists seeking innovative and reliable research tools.

Contacts

Cyagen
China – www.cyagen.com; Tel: 400-680-8038; Email: info@cyagen.com
APAC region – apac.cyagen.com
South Korea – korea.cyagen.com; Tel: 86 20-31601779; Email: service-apac@cyagen.com
Japan – www.cyagen.jp – Tel: 03-6304-1096; Email: service@cyagen.jp
North America and Europe – www.cyagen.com; Tel: +1-800-921-8930 (8-6pm PST) or +1-408-969-0306 (int'l); Email: service@cyagen.com

genOway
Tel: +33 (0)4 37 65 41 00; Email: info@genoway.com

Other news & events

8th Annual Tumour Models, San Francisco, CA, Jan 30-Feb 01, 2024
Conference
genOway talk
Event
-
Jan 2024
Read on
Another technological achievement for genOway's humanized ICP (immune checkpoint) models, used successfully by Curadev Pharma in the preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers
2023
IND (Investigational New Drug)
News
-
Aug 2023
Read on
Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance
2022
Intellectual property
News
-
Sep 2022
Read on
genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology
2022
Intellectual property
News
-
Jan 2022
Read on
ERS Genomics and genOway enter CRISPR/Cas9 agreement
2021
Intellectual property
News
-
Jun 2021
Read on